- Data presented at ESMO in September provided clinical proof of concept for the intravenous administration of Transgene’s patented oncolytic virus (Invir.IO™ platform)—significantly expanding the market opportunity
- First data from two ongoing Phase I trials of the individualized cancer vaccine TG4050 (myvac® platform) will be communicated in the second half of November 2021
- €40.9 million in cash and cash equivalents as of September 30, 2021, further strengthened by the €17.4 million received in October 2021 from the partial sale of Tasly BioPharmaceuticals shares
- Financial visibility until the end of 2023
.../...
0 commentaire
Vous devez être membre pour ajouter un commentaire.
Vous êtes déjà membre ? Connectez-vous
Pas encore membre ? Devenez membre gratuitement
Signaler le commentaire
Fermer